Literature DB >> 1440200

A role for major histocompatibility complex-binding peptides in the immunotherapy of autoimmune disease.

D C Wraith1, D E Smilek.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1440200     DOI: 10.1007/bf00197134

Source DB:  PubMed          Journal:  Springer Semin Immunopathol        ISSN: 0344-4325


× No keyword cloud information.
  24 in total

Review 1.  MHC-binding peptides for immunotherapy of experimental autoimmune disease.

Authors:  D C Wraith; D E Smilek; S Webb
Journal:  J Autoimmun       Date:  1992-04       Impact factor: 7.094

Review 2.  T cell recognition as the target for immune intervention in autoimmune disease.

Authors:  D C Wraith; H O McDevitt; L Steinman; H Acha-Orbea
Journal:  Cell       Date:  1989-06-02       Impact factor: 41.582

3.  Inhibition of experimental autoimmune encephalomyelitis induction in SJL/J mice by using a peptide with high affinity for IAs molecules.

Authors:  A G Lamont; A Sette; R Fujinami; S M Colón; C Miles; H M Grey
Journal:  J Immunol       Date:  1990-09-15       Impact factor: 5.422

4.  Selective in vivo inhibition of T cell activation by class II MHC-binding peptides administered in soluble form.

Authors:  S Muller; L Adorini; A Juretic; Z A Nagy
Journal:  J Immunol       Date:  1990-12-15       Impact factor: 5.422

5.  Antigen recognition in autoimmune encephalomyelitis and the potential for peptide-mediated immunotherapy.

Authors:  D C Wraith; D E Smilek; D J Mitchell; L Steinman; H O McDevitt
Journal:  Cell       Date:  1989-10-20       Impact factor: 41.582

6.  Autoimmune disease: immunotherapy by peptides?

Authors:  C A Janeway
Journal:  Nature       Date:  1989-10-12       Impact factor: 49.962

7.  Structure of the human class I histocompatibility antigen, HLA-A2.

Authors:  P J Bjorkman; M A Saper; B Samraoui; W S Bennett; J L Strominger; D C Wiley
Journal:  Nature       Date:  1987 Oct 8-14       Impact factor: 49.962

8.  Restricted use of T cell receptor V genes in murine autoimmune encephalomyelitis raises possibilities for antibody therapy.

Authors:  J L Urban; V Kumar; D H Kono; C Gomez; S J Horvath; J Clayton; D G Ando; E E Sercarz; L Hood
Journal:  Cell       Date:  1988-08-12       Impact factor: 41.582

9.  MHC control of CD4+ T cell subset activation.

Authors:  J S Murray; J Madri; J Tite; S R Carding; K Bottomly
Journal:  J Exp Med       Date:  1989-12-01       Impact factor: 14.307

10.  Inhibition of antigen-specific T lymphocyte activation by structurally related Ir gene-controlled polymers. Evidence of specific competition for accessory cell antigen presentation.

Authors:  K L Rock; B Benacerraf
Journal:  J Exp Med       Date:  1983-05-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.